Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States) (original) (raw)

Abstract

Obesity is a risk factor for colon cancer, possibly due to elevated levels of circulating cytokines derived from adipose tissue. Aspirin, which may affect the levels of these cytokines, has been shown in randomized controlled trials to decrease the risk of colorectal adenomas. We hypothesized that the chemopreventive effect of aspirin might be greater in individuals with higher body mass index (BMI). Data were available from the Aspirin/Folate Polyp Prevention Study, a randomized controlled trial of aspirin and folic acid to prevent recurrent colorectal adenomas. Obesity was defined as BMI ≥ 30 (kg/m2), overweight as BMI of 25–29 (kg/m2) and normal weight as BMI <25 (kg/m2). For the analysis of the effect of aspirin on the recurrence of colorectal adenoma by BMI, we computed risk ratios for aspirin versus placebo within the three BMI strata using a modified Poisson model. Overall the risk reduction of adenomas with a daily dose of 325 mg aspirin was greater among subjects with higher BMI. Among obese subjects the risk ratio (RR) for advanced adenomas compared with placebo was 0.44 (95% CI 0.17–1.10), versus RR = 1.23 (95% CI 0.55–2.77) among those with normal weight. However, 81 mg aspirin daily did not interact with BMI to modify the risk of adenomas in such a fashion. The more pronounced effect of 325 mg aspirin in individuals with higher BMI suggests a possible protective role of anti-inflammatory aspirin against increased adipose-driven cytokines among obese subjects.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Murphy TK, Calle EE, Rodriguez C, Kahn HS, Thun MJ (2000) Body Mass index and colon cancer mortality in a large prospective study. Am J Epidemiol 152: 847–854
    Article PubMed CAS Google Scholar
  2. Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4: 579–91
    Article PubMed CAS Google Scholar
  3. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC (1995) Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 122: 327–334
    PubMed CAS Google Scholar
  4. Giovannucci E, Colditz GA, Stampfer MJ, Willett WC (1996) Physical activity, obesity, and risk of colorectal adenoma in women (United States). Cancer Causes Control 7: 253–263
    Article PubMed CAS Google Scholar
  5. Terry MB, Neugut AI, Bostick RM, Sandler RS, Haile RW, Jacobson JS (2002) Risk factors for advanced colorectal adenomas: a pooled analysis. Cancer Epidemiol Biomarkers Prev 11: 622–629
    PubMed Google Scholar
  6. Almendingen K, Hofstad B, Vatn MH (2001) Does high body fatness increase the risk of presence and growth of colorectal adenomas followed up in situ for 3 years? Am J Gastroenterol 96: 2238–2246
    Article PubMed CAS Google Scholar
  7. Calle EE, Thun MJ (2004) Obesity and cancer. Oncogene 23: 6365–6378
    Article PubMed CAS Google Scholar
  8. Das UN (2001) Is obesity an inflammatory condition? Nutrition 17: 953–966
    Article PubMed CAS Google Scholar
  9. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ (2004) C-reactive protein and the risk of incident colorectal cancer. JAMA 291: 585–590
    Article PubMed CAS Google Scholar
  10. Zhang SM, Buring JE, Lee IM, Cook NR, Ridker PM (2005) C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med 142: 425–432
    PubMed CAS Google Scholar
  11. Baron JA, Cole BF, Sandler RS et al (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348: 891–899
    Article PubMed CAS Google Scholar
  12. Sandler RS, Halabi S, Baron JA et al (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. New Engl J Med 348: 883–890
    Article PubMed CAS Google Scholar
  13. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM (2004) Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215: 1–20
    Article PubMed CAS Google Scholar
  14. Macarthur M, Hold GL, El Omar EM (2004) Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 286: G515–G520
    Article PubMed CAS Google Scholar
  15. Macarthur M, Hold GL, El Omar EM (2004) Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 286: G515–G520
    Article PubMed CAS Google Scholar
  16. WHO Consultation on Obesity. Obesity: Preventing and managing the Global Epidemic. 894. 1997. Geneva, World Health Organization. WHO Technical Report Series (TRS)
  17. Zou G (2004) A Modified Poisson Regression Approach to Prospective Studies with Binary Data. Am J Epidemiol 159: 702–706
    Article PubMed Google Scholar
  18. Greenland S (2004) Model-based estimation of relative risks and Other epidemiologic measures in studies of common outcomes and in case-control Studies. Am J Epidemiol 160: 301–305
    Article PubMed Google Scholar
  19. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P (1999) Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 100: 793–798
    PubMed CAS Google Scholar
  20. Solheim S, Arnesen H, Eikvar L, Hurlen M, Seljeflot I (2003) Influence of aspirin on inflammatory markers in patients after acute myocardial infarction. Am J Cardiol 92: 843–845
    Article PubMed CAS Google Scholar
  21. Feldman M, Jialal I, Devaraj S, Cryer B (2001) Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 37: 2036–2041
    Article PubMed CAS Google Scholar
  22. Feng D, Tracy RP, Lipinska I, Murillo J, McKenna C, Tofler GH (2000) Effect of short-term aspirin use on C-reactive protein. J Thromb Thrombolysis 9: 37–41
    Article PubMed CAS Google Scholar
  23. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G (2004) Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 234S–64S
    Article PubMed CAS Google Scholar
  24. Feldman M, Jialal I, Devaraj S, Cryer B (2001) Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 37: 2036–2041
    Article PubMed CAS Google Scholar

Download references

Author information

Authors and Affiliations

  1. Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, NC, USA
    Sangmi Kim
  2. Department of Community and Family Medicine, Dartmouth Medical School, Lebanon, NH, USA
    John A. Baron, Leila A. Mott & Bernard F. Cole
  3. Department of Gastroenterology and Hepatology, Cleveland Clinic Foundation, Cleveland, OH, USA
    Carol A. Burke
  4. Health Studies, Division of Environmental Health Sciences, School of Public Health, University of Minnesota, Minneapolis, MN, USA
    Timothy R. Church
  5. Department of Public Health Sciences and Nutritional Sciences, University of Toronto, Toronto, Canada
    Gail E. McKeown-Eyssen
  6. Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA
    Robert W. Haile
  7. Center for Gastrointestinal Biology and Disease, University of North Carolina, CB#7555, 4111 Bioinformatics Building, Chapel Hill, NC, 27599-7555, USA
    Robert S. Sandler

Authors

  1. Sangmi Kim
  2. John A. Baron
  3. Leila A. Mott
  4. Carol A. Burke
  5. Timothy R. Church
  6. Gail E. McKeown-Eyssen
  7. Bernard F. Cole
  8. Robert W. Haile
  9. Robert S. Sandler

Corresponding author

Correspondence toRobert S. Sandler.

Additional information

This work was supported in part by grants from the National Institutes of Health P30 DK34987, R01 CA59005, RR000046.

Rights and permissions

About this article

Cite this article

Kim, S., Baron, J.A., Mott, L.A. et al. Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States).Cancer Causes Control 17, 1299–1304 (2006). https://doi.org/10.1007/s10552-006-0075-x

Download citation

Keywords